Publication | Closed Access

Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial

HypertensionPatiromer Versus PlaceboCardiovascular DiseaseMedicineAntihypertensive TherapyChronic Kidney DiseaseClinical TrialsPharmacotherapyPharmacologic InterventionSpironolactone UsePharmacologyNephrologyAnesthesiology